Level
Posts: 25145
Joined: 3/3/2006 Status: offline
|
MONDAY, Jan. 14 (HealthDay News)-- The long-awaited results of a trial of Zetia, a cholesterol-lowering drug prescribed to about a million Americans, shows the drug confers no medical benefit to users. In fact, the pace at which artery-clogging plaques formed within vessels almost doubled in patients taking Zetia (ezetimibe) along with another cholesterol-lowering drug, Zocor (simvastatin), compared to those taking Zocor alone, the study found. The two medications -- ezetimibe plus simvastatin -- are also marketed in one prescription pill, called Vytorin. About 60 percent of U.S. patients who are taking Zetia now receive the drug as part of Vytorin. But the new two-year trial of 720 patients sheds doubt on whether it makes any sense for people battling cholesterol to take Vytorin versus Zocor alone, experts said. The study was funded by the two companies that make Zetia, Merck and Schering-Plough. "This wraps it up," said Dr. Steven E. Nissen, chairman of cardiology at the Cleveland Clinic. "That's all there is. There just isn't any evidence that adding ezetimibe to simvastatin produces any advantage." http://news.yahoo.com/s/hsn/20080115/hl_hsn/cholesteroldrugzetiadoesntcutheartattackriskstudy
_____________________________
Fake the heat and scratch the itch Skinned up knees and salty lips Let go it's harder holding on One more trip and I'll be gone ~~ Stone Temple Pilots
|